Abstract
Anaplastic thyroid carcinoma (ATC) is considered to be one of the most aggressive cancers. Our previous study proved that highly expressed lysine acetyltransferase 5 (KAT5) in ATC is associated with a poorer prognosis. Here, this study examined the effects of a KAT5 inhibitor (NU9056) in human ATC cells. First, the Cancer Genome Atlas (TCGA) dataset was used to detect the relationship between KAT5 expression and outcomes of thyroid carcinoma patients. Then, both in vitro and in vivo experiments were conducted to investigate the effects of NU9056 on normal and ATC human thyroid cells. Finally, microRNA sequencing, qPCR, and dual-luciferase reporter assay were performed to explore potential mechanisms by identifying downstream microRNA related to NU9056. KAT5 dysregulation correlated with more advanced-stage and poorer outcomes of thyroid carcinoma patients. Endogenous KAT5 protein and mRNA levels were much higher in ATC cells than in normal thyroid cells. Suppression of KAT5 by NU9056 inhibited survival, growth, migration, invasion, and tube formation, and increased radiosensitivity and chemosensitivity in ATC cells but showed no impact on normal thyroid cells. Mechanistically, microRNA-202-5p (miR-202) was identified as the most significantly decreased miRNA after NU9056 treatment. Knockdown of miR-202 suppressed ATC cell progression, while forced expression of miR-202 partially blocked the inhibitory effect of NU9056 on ATC cells. Furthermore, c-Myc was validated as the transcription factor of miR-202, and NU9056 decreased the c-Myc protein level by shortening its half-life. Finally, we proved that NU9056 inhibited ATC proliferation in vivo. Our results indicated that NU9056 targets KAT5, shortens c-Myc half-life, subsequently downregulates miR-202 expression, and results in the suppression of ATC cells. Overall, KAT5 could be a potential target for clinical treatment for ATC.
Highlights
Anaplastic thyroid carcinoma (ATC) is highly malignant due to its proliferative capacity and invasive nature [1,2]. e prognosis of ATC patients still remains extremely poor, with a median survival of only around 5–6 months [1,2]. us, in spite of its rarity, ATC accounts for around half of thyroid cancer-related death [1,2]
In a dataset that contains 500 papillary thyroid cancer patients (TCGA, PanCancer Atlas), we found that KAT5 alteration cases had more advanced T stages and poorer survival than KAT5 normally expressed ones (Figures 1(a)-1(c))
We found that endogeneous KAT5 expressions were much higher in ATC cell lines (8505C and CAL-62) than in a normal thyroid cell line (Nthy-ori 3–1) at both protein and mRNA levels (Figures 2(a), 2(b))
Summary
Anaplastic thyroid carcinoma (ATC) is highly malignant due to its proliferative capacity and invasive nature [1,2]. e prognosis of ATC patients still remains extremely poor, with a median survival of only around 5–6 months [1,2]. us, in spite of its rarity, ATC accounts for around half of thyroid cancer-related death [1,2]. There have been several suggestions as to mechanisms driving ATC progression, treatment with agents that target these mechanisms does not improve the prognosis of ATC patients [3–5]. Our previous study proved that highly expressed lysine acetyltransferase 5 (KAT5) in ATC is associated with a poorer prognosis. The Cancer Genome Atlas (TCGA) dataset was used to detect the relationship between KAT5 expression and outcomes of thyroid carcinoma patients. KAT5 dysregulation correlated with more advanced-stage and poorer outcomes of thyroid carcinoma patients. Suppression of KAT5 by NU9056 inhibited survival, growth, migration, invasion, and tube formation, and increased radiosensitivity and chemosensitivity in ATC cells but showed no impact on normal thyroid cells. Our results indicated that NU9056 targets KAT5, shortens c-Myc half-life, subsequently downregulates miR-202 expression, and results in the suppression of ATC cells. KAT5 could be a potential target for clinical treatment for ATC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
